Literature DB >> 29016090

Managing actinic keratosis in primary care.

Nicola Salmon, Michael J Tidman.   

Abstract

Actinic, or solar, keratosis is caused by chronic ultraviolet-induced damage to the epidermis. In the UK, 15-23% of individuals have actinic keratosis lesions. Risk factors include: advanced age; male gender; cumulative sun exposure or phototherapy; Fitzpatrick skin phototypes I-II; long-term immuno-suppression and genetic syndromes e.g. xeroderma pigmentosum and albinism. Actinic keratoses are regarded by some authorities as premalignant lesions that may transform into invasive squamous cell carcinoma (SCC) and by others as in situ SCC that may progress to an invasive stage. The risk of malignant change appears low; up to 0.5% per lesion per year. Up to 20-30% of lesions may spontaneously regress but in the absence of any reliable prognostic clinical indicators regarding malignant potential active treatment is considered appropriate. Actinic keratosis lesions may present as discrete hyperkeratotic papules, cutaneous horns, or more subtle flat lesions on sun-exposed areas of skin. The single most helpful diagnostic sign is an irregularly roughened surface texture: a sandpaper-like feel almost always indicates actinic damage. Dermatoscopy can be helpful in excluding signs of basal cell carcinoma when actinic keratosis is non-keratotic. It is always important to consider the possibility of SCC. The principal indication for referral to secondary care is the possibility of cutaneous malignancy. However, widespread and severe actinic damage in patients who are immunosuppressed is also a reason for referral.

Entities:  

Mesh:

Year:  2016        PMID: 29016090

Source DB:  PubMed          Journal:  Practitioner        ISSN: 0032-6518


  1 in total

Review 1.  Risk Factors for Actinic Keratoses: A Systematic Review and Meta-Analysis.

Authors:  Yongshuang Li; Jinhua Wang; Weimian Xiao; Jing Liu; Xushan Zha
Journal:  Indian J Dermatol       Date:  2022 Jan-Feb       Impact factor: 1.757

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.